In Alzheimer's, the 'juggernaut is changing course,' says TauRx chief exec
Jul 24 - 2017 01:13 PM
As a lifelong follower of the ‘tau hypothesis,' TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years.
A new view of twisted proteins could help scientists understand Alzheimer's
Jul 24 - 2017 01:11 PM
A new study published this month in Nature marks a key milestone in Alzheimer's research. It demonstrates the first complete model of a tau filament, a protein structure found in the brain cells of Alzheimer's patients and thought to be the cause of the neurodegenerative disease.
NCTalks with Claude Wischik: targeting tau to combat Alzheimer’s disease
Jun 13 - 2017 06:29 PM
In this NCTalks podcast, Lauren Pulling, Editor of Neuro Central, is joined by Claude Wischik. A pioneer in tau research, he discovered the tau protein compositional structure of Alzheimer’s tangles and established that it was possible to dissolve these tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors.
“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec
Apr 12 - 2017 01:10 PM
The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed.
Targeting tau protein in Alzheimer's disease
Nov 16 - 2016 11:20 AM
Alzheimer's disease, the most common dementing illness, is a relentlessly progressive and fatal brain disorder that begins approximately 10–15 years before any symptoms manifest.